A patient group this summer accused Taysha Gene Therapies of breaching a contract to develop a therapy for an ultra-rare condition, another sign of deep tensions between the company and family foundations.
In July, Hannah’s Hope Fund claimed that Taysha breached a licensing agreement that called for the company to…
Click here to view original post
